BridgeBio Pharma (NASDAQ:BBIO) Director Sells $6,011,788.80 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 90,240 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $66.62, for a total value of $6,011,788.80. Following the completion of the sale, the director directly owned 6,589 shares of the company’s stock, valued at $438,959.18. The trade was a 93.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Trading Up 1.1%

BridgeBio Pharma stock traded up $0.75 during midday trading on Wednesday, reaching $67.39. The stock had a trading volume of 1,601,496 shares, compared to its average volume of 2,772,661. BridgeBio Pharma, Inc. has a 12 month low of $39.65 and a 12 month high of $84.94. The company has a market capitalization of $13.20 billion, a P/E ratio of -18.02 and a beta of 0.97. The company has a fifty day moving average price of $69.99 and a two-hundred day moving average price of $72.07.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The company had revenue of $194.52 million during the quarter, compared to analyst estimates of $178.07 million. During the same period last year, the firm earned ($0.88) earnings per share. BridgeBio Pharma’s quarterly revenue was up 66.8% compared to the same quarter last year. On average, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in BridgeBio Pharma by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after purchasing an additional 347,074 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of BridgeBio Pharma by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after buying an additional 2,178,556 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of BridgeBio Pharma by 9.8% in the 4th quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after buying an additional 806,463 shares during the last quarter. Aisling Capital Management LP boosted its stake in shares of BridgeBio Pharma by 0.4% in the 3rd quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock worth $316,294,000 after buying an additional 21,486 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after buying an additional 902,648 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BBIO. Oppenheimer decreased their target price on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. Mizuho cut their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a research note on Tuesday. Royal Bank Of Canada began coverage on BridgeBio Pharma in a research note on Thursday, April 9th. They set an “outperform” rating and a $100.00 price target for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of BridgeBio Pharma in a research note on Thursday, May 28th. Twenty-two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $91.05.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.